Endo Pharmaceuticals is to pay ProStrakan $210 million for the US licensing and distribution rights to the UK firm's yet to be approved 2% testosterone gel Fortigel.
Endo Pharmaceuticals is to pay ProStrakan $210 million for the US licensing and distribution rights to the UK firm's yet to be approved 2% testosterone gel Fortigel.
The exclusive licensing and distribution agreement allows Endo to sell the testosterone replacement therapy, which it plans to market as Fortesta, in male hypogonadism in the US
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.
The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.
